Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Aug;252(8):875-84.
doi: 10.1007/s00415-005-0922-9.

The natural course of non-classic Pompe's disease; a review of 225 published cases

Affiliations
Review

The natural course of non-classic Pompe's disease; a review of 225 published cases

Léon P F Winkel et al. J Neurol. 2005 Aug.

Abstract

Pompe's disease is a neuromuscular disorder caused by deficiency of lysosomal acid alpha-glucosidase. Recombinant human alpha- glucosidase is under evaluation as therapeutic drug. In light of this development we studied the natural course of cases not fitting the definition of classic infantile Pompe's disease. Our review of 109 reports including 225 cases shows a continuous spectrum of phenotypes. The onset of symptoms ranged from 0 to 71 years. Based on the available literature, no criteria to delineate clinical sub-types could be established.A common denominator of these cases is that first symptoms were related to or caused by muscle weakness. In general, patients with a later onset of symptoms seemed to have a better prognosis. Respiratory failure was the most frequent cause of death. CK, LDH, ASAT, ALAT and muscle glycogen levels were frequently but not always elevated. In most cases a muscle biopsy revealed lysosomal pathology, but normal muscle morphology does not exclude Pompe's disease. In 10% of the cases in which the enzyme assay on leukocytes was used, a normal alpha-glucosidase activity was reported. Data on skeletal muscle strength and function, pulmonary function, disability, handicap and quality of life were insufficiently reported in the literature. Studies of non-classic Pompe's disease should focus on these aspects, before enzyme replacement therapy becomes generally available.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. J Inherit Metab Dis. 1990;13(3):283-4 - PubMed
    1. Muscle Nerve Suppl. 1995;3:S61-9 - PubMed
    1. Funct Neurol. 1996 Mar-Jun;11(2-3):105-10 - PubMed
    1. J Neurol Sci. 1976 Nov;30(1):155-66 - PubMed
    1. Eur J Clin Invest. 1974 Dec 5;4(6):429-33 - PubMed

Publication types

MeSH terms

LinkOut - more resources